This multi-center retrospective study (RICE) evaluated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with cervical and endometrial cancer who had previously received ICI therapy.
Retrospective design limits causal inference; multi-center data may introduce heterogeneity in treatment protocols and patient selection; specific outcome data (response rates, survival figures) are not available from the provided abstract.
Clinicians managing recurrent gynecologic cancers should be aware of emerging data on ICI rechallenge as a potential strategy, though the evidence base remains observational and practice-guiding numbers are pending full publication review.
Explore related topics
